News @ Qprotyn

Changing the world, one mAb at a time.

We are always pushing the frontier of technology’s impact in the world of biologics. We feel that modern technology allows easy crossover of ideas across borders and cultures. Our achievements and our knowledge are to be shared with the community and the technology ecosystem.

Catalent and Bhami Research Laboratory Enter into Licensing Agreement

Delivering High-Concentration Biologics Subcutaneously https://biologics.catalent.com/catalent-news/catalent-and-bhami-research-laborator...

Janak Vadgama

Mar 28, 20233 min read

Ocular diseases and the rise of Biologics in the field of Ophthalmology

Speaking at the American Academy of Optometry 2021 annual meeting in Boston, Anthony DeWilde, OD, FAAO, discussed biologics, which hold...

Janak Vadgama

Dec 7, 20212 min read

Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO® technology.

Upgrading Trastuzumab from IV to Subcutaneous (SubQ) administration may now be possible without expensive, high-volume hyaluronidase...

Janak Vadgama

Sep 3, 20212 min read

Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO® technology.

Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology Innovator...

Janak Vadgama

Aug 5, 20212 min read